Condition

Her-2 Negative Breast Cancer clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Her-2 Negative Breast Cancer clinical trials that are recruiting, in China. By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Her-2 Negative Breast Cancer clinical trials

StudyPhaseWhereStatusRegistered
Eribulin plus anlotinib for HER2‑negative recurrent or metastatic breast cancer after ADCs Phase 2 Guangzhou Recruiting Apr 9, 2026
Combination therapy for early breast cancer with HRR gene mutation Phase 2 Guangzhou, Guangdong Recruiting Mar 9, 2023
Utidelone plus bevacizumab for people with HER2-negative advanced breast cancer after at least two prior treatments Phase 2 Zhengzhou, Henan Recruiting Jun 1, 2022

All recruiting trials (3)

Related topics

AnlotinibBevacizumabCamrelizumab

Quick answers

How many Her-2 Negative Breast Cancer clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.